• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.

作者信息

Correia-Melo Fernanda S, Silva Samantha S, Araújo-de-Freitas Lucas, Quarantini Lucas C

机构信息

Serviço de Psiquiatria, Hospital Escola, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil.

Programa de Pós-Graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, UFBA, Salvador, BA, Brazil.

出版信息

Braz J Psychiatry. 2017 Apr-Jun;39(2):188-189. doi: 10.1590/1516-4446-2016-2070.

DOI:10.1590/1516-4446-2016-2070
PMID:28591272
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7111455/
Abstract
摘要

相似文献

1
S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.S-(+)-氯胺酮诱发的分离症状作为难治性抑郁症患者的一种创伤性体验。
Braz J Psychiatry. 2017 Apr-Jun;39(2):188-189. doi: 10.1590/1516-4446-2016-2070.
2
Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.关于氯胺酮和艾司氯胺酮用于治疗抑郁症的前景与担忧。
Acta Psychiatr Scand. 2019 Aug;140(2):182-183. doi: 10.1111/acps.13063.
3
Esketamine nasal spray (Spravato) for treatment-resistant depression.艾氯胺酮鼻喷雾剂（斯帕托）用于治疗抵抗性抑郁症。
Med Lett Drugs Ther. 2019 Apr 8;61(1569):54-57.
4
Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.治疗抵抗性双相情感障碍患者使用氯胺酮的安全性和耐受性与中枢神经系统症状相关：文献综述与分析。
Medicina (Kaunas). 2020 Feb 9;56(2):67. doi: 10.3390/medicina56020067.
5
Intravenous ketamine for treatment-resistant major depressive disorder.静脉注射氯胺酮治疗难治性重度抑郁症。
Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20.
6
Can we confidently use ketamine as a clinical treatment for depression?我们能否放心地将氯胺酮用作抑郁症的临床治疗手段？
Lancet Psychiatry. 2018 Jan;5(1):11-12. doi: 10.1016/S2215-0366(17)30480-7.
7
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.μ-阿片受体基因多态性 rs1799971(A118G) 对 Esketamine 鼻喷雾剂临床试验中抗抑郁和分离反应的影响。
Int J Neuropsychopharmacol. 2020 Dec 3;23(9):549-558. doi: 10.1093/ijnp/pyaa030.
8
Ketamine helps a third of patients with treatment resistant depression, finds small UK study.英国小型研究发现，氯胺酮对三分之一难治性抑郁症患者有帮助。
BMJ. 2014 Apr 3;348:g2576. doi: 10.1136/bmj.g2576.
9
[Ketamine for treatment of acute depression].[氯胺酮用于治疗急性抑郁症]
Ugeskr Laeger. 2013 Sep 9;175(37):2090-3.
10
Ketamine as an alternative treatment for treatment-resistant depression.氯胺酮作为难治性抑郁症的一种替代治疗方法。
Perspect Psychiatr Care. 2013 Jan;49(1):2-4. doi: 10.1111/ppc.12006. Epub 2012 Dec 30.

引用本文的文献

1
Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca-Permeable AMPA Receptors in Mice.氯胺酮通过小鼠中钙通透性AMPA受体的表达逆转慢性应激诱导的行为变化。
FASEB J. 2025 Aug 31;39(16):e70891. doi: 10.1096/fj.202501763R.
2
How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.接受氯胺酮治疗精神疾病的人对这种干预措施的主观体验如何？一项定性研究的元综合分析。
Int J Ment Health Nurs. 2025 Feb;34(1):e13425. doi: 10.1111/inm.13425. Epub 2024 Sep 16.
3
Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study.病例报告：通过重复输注氯胺酮维持意识改变状态可能是促进持久抗抑郁作用的关键：一项个性化给药单病例研究的初步经验教训。
Front Psychiatry. 2023 Oct 25;14:1197697. doi: 10.3389/fpsyt.2023.1197697. eCollection 2023.
4
The parable of the Therapeutic Goods Administration approval of esketamine (Spravato) in Australia.澳大利亚治疗商品管理局批准 Esketamine（Spravato）的寓言。
Australas Psychiatry. 2023 Apr;31(2):186-189. doi: 10.1177/10398562231156475. Epub 2023 Feb 20.
5
The antidepressant effect and safety of non-intranasal esketamine: A systematic review.非鼻腔内用依他佐辛的抗抑郁作用和安全性：系统评价。
J Psychopharmacol. 2022 May;36(5):531-544. doi: 10.1177/02698811221084055. Epub 2022 May 12.
6
Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.艾司氯胺酮与消旋氯胺酮治疗难治性抑郁症的比较研究：一项非劣效性临床试验方案
Medicine (Baltimore). 2018 Sep;97(38):e12414. doi: 10.1097/MD.0000000000012414.
7
Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials.金刚烷胺的潜在抗抑郁作用：临床前研究和临床试验的综述。
Braz J Psychiatry. 2018 Oct-Dec;40(4):449-458. doi: 10.1590/1516-4446-2017-2393. Epub 2018 Jun 11.

本文引用的文献

1
Ketamine administration in depressive disorders: a systematic review and meta-analysis.氯胺酮在抑郁症治疗中的应用：一项系统综述和荟萃分析。
Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20.
2
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.一项关于氯胺酮快速治疗重度抑郁发作的随机、双盲、安慰剂对照试验的系统评价和荟萃分析。
Psychol Med. 2015 Mar;45(4):693-704. doi: 10.1017/S0033291714001603. Epub 2014 Jul 10.
3
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.氯胺酮在情感障碍中的应用综述：临床疗效的现有证据、使用限制以及作用机制的临床前证据。
J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10.
4
Repeated S-ketamine infusions in therapy resistant depression: a case series.重复静脉注射S-氯胺酮治疗难治性抑郁症：病例系列
J Clin Pharmacol. 2013 Sep;53(9):996-8. doi: 10.1002/jcph.122. Epub 2013 Jul 24.
5
A review of acute stress disorder in DSM-5.DSM-5 中急性应激障碍的综述。
Depress Anxiety. 2011 Sep;28(9):802-17. doi: 10.1002/da.20737. Epub 2010 Nov 3.